Carnegie

Doktor.se is a digital healthcare company based in Sweden that focuses on providing modern and personalized care. With multiple offices across the country, it is in a phase of rapid expansion. The company employs experienced specialist nurses, doctors, and psychologists to deliver quick and effective medical services to its members. Doktor.se offers a range of services, including counseling, appointment scheduling, remote care, prescriptions, and referrals, all managed through their user-friendly app. As an approved healthcare provider, their services are delivered by certified professionals, ensuring quality care. Additionally, Doktor.se owns physical primary care facilities, allowing them to streamline access to healthcare and alleviate the burden on traditional medical systems. Their comprehensive approach not only enhances patient experience but also includes exclusive health offers and informative content tailored to client needs.

Doktor.se is a digital healthcare company based in Sweden that focuses on providing modern and personalized care. With multiple offices across the country, it is in a phase of rapid expansion. The company employs experienced specialist nurses, doctors, and psychologists to deliver quick and effective medical services to its members. Doktor.se offers a range of services, including counseling, appointment scheduling, remote care, prescriptions, and referrals, all managed through their user-friendly app. As an approved healthcare provider, their services are delivered by certified professionals, ensuring quality care. Additionally, Doktor.se owns physical primary care facilities, allowing them to streamline access to healthcare and alleviate the burden on traditional medical systems. Their comprehensive approach not only enhances patient experience but also includes exclusive health offers and informative content tailored to client needs.

Agilyx is a developer of advanced conversion technologies aimed at promoting a circular economy for plastics, specifically polystyrene and polymethyl methacrylate. The company focuses on transforming post-use plastics into valuable resources, such as oils and chemical substrates, through its comprehensive waste sourcing and processing solutions. By co-founding Cyclyx International, Agilyx collaborates with industry partners to create tailored plastic recovery programs, enhancing the overall plastic recycling ecosystem. This initiative aligns with Agilyx's mission to facilitate the chemical recycling of plastics on a global scale, thereby contributing to a low-carbon economy and enabling the recycling market to effectively manage waste plastics. The majority of Agilyx's revenue is generated from its Cyclyx segment, underscoring its commitment to innovative waste management and recycling practices.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases. These conditions represent areas of high unmet medical need, often involving orphan and niche indications that currently lack effective therapies. The company focuses on various therapeutic segments, including neuro-ophthalmological, pulmonary, and neuromuscular diseases. Santhera primarily generates its revenue from the European Union, aiming to address significant health challenges faced by patients with these rare disorders.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases. These conditions represent areas of high unmet medical need, often involving orphan and niche indications that currently lack effective therapies. The company focuses on various therapeutic segments, including neuro-ophthalmological, pulmonary, and neuromuscular diseases. Santhera primarily generates its revenue from the European Union, aiming to address significant health challenges faced by patients with these rare disorders.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest such population worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations.

Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

ZoomON's software enables anyone with a browser to view, mark-up, design and collaborate on complex, and simple, graphics. This includes maps, product drawings and product catalogs. Their software cuts across proprietary technologies and unleashes the details anytime, anywhere!